Innoviva Inc
INVA
查看详细走势图
19.770USD
+0.260+1.33%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.48B总市值
10.02市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.33%
5天
-1.40%
1月
-7.14%
6月
-4.40%
今年开始到现在
+13.95%
1年
+11.19%
查看详细走势图
TradingKey Innoviva Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Innoviva Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在药品行业排名31/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价32.25。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Innoviva Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
买入
评级
32.250
目标均价
+53.57%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Innoviva Inc亮点
亮点风险
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Innoviva Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Innoviva Inc简介
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
公司代码INVA
公司Innoviva Inc
CEORaifeld (Pavel)
网址https://www.inva.com/
常见问题
Innoviva Inc(INVA)的当前股价是多少？
Innoviva Inc(INVA)的当前股价是 19.770。
Innoviva Inc的股票代码是什么？
Innoviva Inc的股票代码是INVA。
Innoviva Inc股票的52周最高点是多少？
Innoviva Inc股票的52周最高点是22.760。
Innoviva Inc股票的52周最低点是多少？
Innoviva Inc股票的52周最低点是16.520。
Innoviva Inc的市值是多少？
Innoviva Inc的市值是1.48B。
Innoviva Inc的净利润是多少？
Innoviva Inc的净利润为23.39M。
现在Innoviva Inc(INVA)的股票是买入、持有还是卖出？
根据分析师评级，Innoviva Inc(INVA)的总体评级为买入，目标价格为32.250。
Innoviva Inc(INVA)股票的每股收益（EPS TTM）是多少
Innoviva Inc(INVA)股票的每股收益（EPS TTM）是1.973。
相关品种
